Zomedica Corp. (ZOMDF) company profile
Close on Oct 19, 2026Market cap $77.40MP/E –Yield –
About Zomedica
Pharmaceutical Preparations, SIC 2834
Zomedica Corp. is an animal health company that develops, manufactures, and markets diagnostic and therapeutic medical devices for companion animals, including dogs, cats, and horses. Its diagnostic offerings include the TRUFORMA point-of-care acoustic wave testing platform, the TRUVIEW automated digital microscopy and cytology system, and the VETGuardian zero-touch vital signs remote monitoring device. Its therapeutic portfolio features PulseVet electrohydraulic shockwave therapy equipment, Assisi targeted pulsed electromagnetic field devices, and VETIGEL hemostatic gel. The company primarily serves clinical veterinarians, veterinary practices, and pet owners.
The company operates manufacturing and distribution facilities in Roswell, Georgia, and a research, development, and manufacturing center in Plymouth, Minnesota. It serves clinical customers in the United States directly through internal sales representatives and domestic distributors. Outside the United States, it commercializes therapeutic products through international distribution networks and a wholly owned subsidiary in Japan. The provided text specifies operational facilities but does not identify the city or address of the corporate headquarters.
Summary of the business section of Zomedica's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Zomedica Corp.
- Founded
- 2013
- Headquarters
- Ann Arbor, MI
- Address
- 1101 Technology Drive, Suite 100 48108
- Phone
- (734) 369-2555
- Website
- zomedica.com
- Employees
- 141, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A0
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Southfield, Michigan
Stock & identifiers
- Ticker
- ZOMDF
- Former tickers
- ZOM until Mar 5, 2025
- Exchange
- OTC
- IPO date
- Nov 21, 2017
- Shares outstanding
- 980M, Aug 5, 2026
- Public float
- $38.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1684144
- CUSIP
- 98980M109
- ISIN
- CA98980M1095
- FIGI
- BBG00DGZC7Y0
- Share class FIGI
- BBG004H67DQ5
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Larry C. Heaton Ii | CEO, Director | 1,250,000 |
| Anthony K. Blair | COO | 1,000,000 |
| Karen DeHaan-Fullerton | General Counsel | 104,300 |
| Russell Kevin Klass | Sr Vice President, Sales | 6,105,000 |
| Scott Jordan | Chief Financial Officer | 300,000 |
| Christopher Ross Macleod | Director | 143,000 |
| Pamela Nichols | Director | – |
| Sean Whelan | Director | – |
| Johnny D. Powers | Director | 4,425,000 |
| Jeffrey M. Rowe | Director | 13,116,127 |
| Robert Cohen | Director | 543,750 |
| Rodney James Williams | Director | 301,900 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2023 | $651.40K | $1.03M | $643.19K | $86960 | – |
| FY2022 | $1.34M | -$128.92K | $732.81K | $70870 | – |
| FY2021 | $5.10M | $2.63M | $415.08K | $133480 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Larry Heaton Chief Executive Officer | $466.40K | $147.27K | $149.21K | $762.88K | – |
| Mike Zuehlke Sr. VP of Finance and Controller(3) | $247.50K | $69.36K | $37.53K | $354.39K | – |
| Tony Blair Chief Operating Officer | $275.53K | $86.65K | $27.98K | $390.15K | +6% |
| Kevin Klass Sr. VP of Sales | $286.40K | $113.00K | $34.00K | $433.40K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 21, 2017
- Exchange
- NYSE American
- First trading day
- Nov 21, 2017
- First-day close
- $2.39
- Lock-up ends (est.)
- May 20, 2018
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 141 employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?